A new treatment, CT041, is bringing hope to patients with advanced pancreatic cancer. This therapy uses modified T-cells to target cancer cells and has shown encouraging results. In a recent study, patients who received CT041 had a median overall survival of 10 months.
Despite some side effects like blood-related issues and digestive problems, the therapy was generally well-tolerated. Out of 24 patients, 70.8% saw their disease controlled, and many experienced a significant reduction in cancer markers.
While these results are promising, more research is needed to fully understand the benefits. If you or a loved one has advanced pancreatic cancer, discuss new treatment options with your doctor.
Read the full article here
Get health updates from Dr Harsh Shah on WhatsApp
Swasth Parivar: twice a month, practical advice on recovery, diet and warning signs. No advertising. Stop any time.
Your number is used for these updates and for the clinic to reach you. It is never sold or passed on. To stop, reply STOP on WhatsApp.